Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial

References

• Patel MM, Widdowson MA, Glass RI, Akazawa K, Vinjé J, Parashar UD. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis. 2008;14(8):1–9. doi:10.3201/eid1408.071114.
   PubMed Web of Science ®Google Scholar
• Hoa Tran TN, Trainor E, Nakagomi T, Cunliffe NA, Nakagomi O. Molecular epidemiology of noroviruses associated with acute sporadic gastroenteritis in children: global distribution of genogroups, genotypes and GII.4 variants. J Clin Virol. 2013;56(3):269–77. doi:10.1016/j.jcv.2012.11.011.
   Web of Science ®Google Scholar
• Payne DC, Vinje J, Szilagyi PG, Edwards KM, Staat MA, Weinberg GA, Hall CB, Chappell J, Bernstein DI, Curns AT, et al. Norovirus and medically attended gastroenteritis in U.S. children. N Engl J Med. 2013;368(12):1121–30. doi:10.1056/NEJMsa1206589.
   PubMed Web of Science ®Google Scholar
• Kõivumägi K, Toompere K, Soeorg H, Kallas E, Jõgeda EL, Huik K, Lutsar I. Acute gastroenteritis hospitalizations after implementation of universal mass vaccination against rotavirus. Vaccine. 2020;38(13):2879–86. doi:10.1016/j.vaccine.2020.01.098.
   PubMed Web of Science ®Google Scholar
• Halasa N, Piya B, Stewart LS, Rahman H, Payne DC, Woron A, Thomas L, Constantine-Renna L, Garman K, McHenry R, et al. The changing landscape of pediatric viral enteropathogens in the post–rotavirus vaccine era. Clin Infect Dis. 2020 Feb 3;72(4):ciaa100. doi:10.1093/cid/ciaa100.
   Web of Science ®Google Scholar
• Quee FA, de Hoog MLA, Schuurman R, Bruijning-Verhagen P. Community burden and transmission of acute gastroenteritis caused by norovirus and rotavirus in the Netherlands (RotaFam): a prospective household-based cohort study. Lancet Infect Dis. 2020;20(5):508–606. doi:10.1016/S1473-3099(20)30058-X.
   Web of Science ®Google Scholar
• Vielot NA, Reyes Y, Blette B, González F, Toval-Ruiz C, Gutiérrez L, Vílchez S, Diez-Valcarce M, Vinjé J, Becker-Dreps S, et al. First episodes of norovirus and sapovirus gastroenteritis protect against subsequent episodes in a Nicaraguan birth cohort. Epidemiology. 2022;33(5):650–3. doi:10.1097/EDE.0000000000001500.
   PubMed Web of Science ®Google Scholar
• Parra GI, Bok K, Taylor R, Haynes JR, Sosnovtsev SV, Richardson C, Green KY. Immunogenicity and specificity of norovirus consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine. 2012;30(24):3580–6. doi:10.1016/j.vaccine.2012.03.050.
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Atmar RL, Frey SE, Gormley R, Chen WH, Ferreira J, Goodwin R, Borkowski A, Clemens R, Mendelman PM. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate—Reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. J Infect Dis. 2014;210(11):1763–71. doi:10.1093/infdis/jiu337.
   PubMed Web of Science ®Google Scholar
• Atmar RL, Baehner F, Cramer JP, Song E, Borkowski A, Mendelman PM, NOR-201 Study Group. Rapid responses to 2 virus-like particle norovirus vaccine candidate formulations in healthy adults: a randomized controlled trial. J Infect Dis. 2016;214(6):845–53. doi:10.1093/infdis/jiw259.
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Cramer JP, Mendelman PM, Sherwood J, Clemens R, Aerssens A, De Coster I, Borkowski A, Baehner F, Van Damme P. Safety and immunogenicity of different formulations of norovirus vaccine candidate in healthy adults: a randomized, controlled, double-blind clinical trial. J Infect Dis. 2018;217(4):597–607. doi:10.1093/infdis/jix572.
   PubMed Web of Science ®Google Scholar
• Atmar RL, Baehner F, Cramer JP, Lloyd E, Sherwood J, Borkowski A, Mendelman PM, Al-Ibrahim MS, Bernstein DL, Brandon DM, et al. Persistence of antibodies to 2 virus-like particle norovirus vaccine candidate formulations in healthy adults: 1-year follow-up with memory probe vaccination. J Infect Dis. 2019;220(4):603–14. doi:10.1093/infdis/jiz170.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Saez-Llorens X, Blazevic V, Lopez P, Lopez E, Masuda T, Mendelman PM, Liu M, Sherwood J, Baehner F, et al. Immunogenicity of a bivalent virus-like particle norovirus vaccine in children from 1 to 8 years of age: a phase 2 randomized, double-blind study. Vaccine. 2022;40(26):3588–96. doi:10.1016/j.vaccine.2022.04.089.
   PubMed Web of Science ®Google Scholar
• Reeck A, Kavanagh O, Estes MK, Opekun AR, Gilger MA, Graham DY, Atmar RL. Serological correlate of protection against Norovirus-induced gastroenteritis. J Infect Dis. 2010;202(8):1212–18. doi:10.1086/656364.
   PubMed Web of Science ®Google Scholar
• Ahmed SM, Hall AJ, Robinson AE, Verhoef L, Premkumar P, Parashar UD, Koopmans M, Lopman BA. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14(8):725–30. doi:10.1016/S1473-3099(14)70767-4.
   PubMed Web of Science ®Google Scholar
• Bhavanam S, Freedman SB, Lee BE, Zhuo R, Qiu Y, Chui L, Xie J, Ali S, Vanderkooi OG, Pang XL, et al. Differences in illness severity among circulating norovirus genotypes in a large pediatric cohort with acute gastroenteritis. Microorganisms. 2020;8(12):1873. doi:10.3390/microorganisms8121873.
   PubMed Web of Science ®Google Scholar
• Saito M, Goel-Apza S, Espetia S, Velasquez D, Cabrera L, Loli S, Crabtree JE, Black RE, Kosek M, Checkley W, et al. Multiple norovirus infections in a birth cohort in a Peruvian periurban community. Clin Infect Dis. 2014;58(4):483–91. doi:10.1093/cid/cit763.
   PubMed Web of Science ®Google Scholar
• Atmar RL, Bernstein DI, Lyon GM, Treanor JJ, Al-Ibrahim MS, Graham DY, Vinjé J, Jiang X, Gregoricus N, Frenck RW, et al. Serological correlates of protection against a GII.4 norovirus. Clin Vaccine Immunol. 2015;22(8):923–9. doi:10.1128/CVI.00196-15.
   PubMedGoogle Scholar
• Chhabra P, Rouhani S, Browne H, Yoir PP, Sala MS, Olortegui MPO, Moulton LH, Kosek MN, Vinje J. Homotypic and heterotypic protection and risk of reinfection following natural norovirus infection in a highly endemic setting. Clin Infect Dis. 2021;72(2):222–9. doi:10.1093/cid/ciaa019.
   PubMed Web of Science ®Google Scholar